"This financing, in addition to a $35M Series D financing closed in March, will enable us to complete our Arikace Phase II program for the treatment of Pseudomonas infections in cystic fibrosis patients," said Tim Whitten, Transave's chief executive officer. "It also allows us to broaden the Arikace clinical trial program by initiating a Phase II clinical trial in a second area of high unmet need: bronchiectasis patients who have pseudomonas lung infections."
Based on the strength of the Arikace clinical profile to date, the company has initiated a Phase II trial to evaluate the compound for treating Pseudomonas infections in patients with non-cystic fibrosis-related bronchiectasis in Europe and India. The U.S. Food and Drug Administration (FDA) has also agreed to the company's plans to expand this trial into the United States. Bronchiectasis is the permanent widening of the bronchi (the large tubes which begin at the bottom of the trachea and branch into the lungs). Individuals with bronchiectasis are vulnerable to recurrent respiratory infections, which often have a Pseudomonas component.
Kristen Kosofsky, managing director of Horizon, noted, "Our goal at Horizon is to support the growth and success of innovative companies like Transave that develop important next-generation technologies that serve as the cornerstone for improving human health and quality of life."
About Arikace (liposomal amikacin for inhalation)
Arikace is a form of the antibiotic amikacin that is enclosed in
nanocapsules of lipid called liposomes. This proprietary next-generation
liposomal technology prolongs release of amikacin in the lung while
minimizing systemic exposure. The treatment uses biocompatible lipids
endogenous to the lung that are formulated into small (0.3 micrometers),
neutrally-charged liposomes that enable biofilm penetration and are highly
efficient, with very low lipid-to-drug ratio (0.65). Arikace can be
effectively delivered thr
|SOURCE Transave, Inc.|
Copyright©2008 PR Newswire.
All rights reserved